Heegon Kim
TECHNOLOGY
Renatus engineers single-isomer cyclodextrins by transforming heterogeneous mixtures into precisely defined molecules optimized for disease-specific cholesterol modulation.
From Heterogeneous Mixtures to Defined Molecules
Hydroxypropyl-β-cyclodextrin (HPβCD) has provided important proof of concept for modulating pathological cholesterol accumulation and has been widely investigated across cholesterol-related diseases. However, HPβCD is a heterogeneous mixture with varying degrees and patterns of substitution, making it difficult to define which molecular structures drive cholesterol interaction, biological activity, safety, and pharmacological properties. This structural complexity limits systematic SAR analysis and rational optimization.
Renatus has developed a library of chemically defined single-isomer cyclodextrins that enable systematic comparison of how structural features influence physicochemical properties, cholesterol modulation, biological activity, and safety.
Disease-Driven Discovery
Pathological cholesterol accumulation differs across diseases in cell type, intracellular location, and biological context. Rather than pursuing a single universal cyclodextrin, Renatus evaluates structurally defined single-isomer cyclodextrins in disease-relevant biological models to identify the molecular features best suited to each disease context. Iterative screening and SAR analysis are then used to connect molecular structure with disease-relevant biological responses.
Our Discovery Strategy
1. Single-Isomer Library
Structurally defined cyclodextrins with systematic molecular variation
2. Physicochemical & Safety Profiling
Cholesterol interaction, solubility, membrane compatibility, and safety
3. Disease-Relevant Biological Screening
Biological activity in models reflecting disease-specific cholesterol pathology
4. SAR Analysis
Link defined molecular structures with biological responses to identify favorable structural features.
